Literature DB >> 10471065

Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.

M Wadelius1, J L Autrup, M J Stubbins, S O Andersson, J E Johansson, C Wadelius, C R Wolf, H Autrup, A Rane.   

Abstract

The development of prostate cancer is dependent on heredity, androgenic influences, and exposure to environmental agents. A high intake of dietary fat is associated with an increased risk of prostate cancer, either through influence on steroid hormone profiles or through production of carcinogenic compounds that require biotransformation by enzymes. The polymorphic glutathione S-transferase (GST), N-acetyltransferase (NAT), and cytochrome P450 (CYP) enzymes are of particular interest in prostate cancer susceptibility because of their ability to metabolize both endogenous and exogenous compounds, including dietary constituents. Association between different NAT2, CYP2D6, CYP2C19 and GSTP1 genotypes and prostate cancer was studied in a Swedish and Danish case-control study comprising 850 individuals. The combined Swedish and Danish study population was analysed by polymerase chain reaction for the NAT2 alleles *4, *5A, *5B, *5C, *6 and *7, and for the CYP2D6 alleles *l, *3 and *4. The Swedish subjects were also analysed for the CYP2C19 alleles *1 and *2, and the GSTP1 alleles *A, *B and *C. No association was found between prostate cancer and polymorphisms in NAT2, CYP2D6, CYP2C19 or GSTP1. An association between CYP2D6 poor metabolism and prostate cancer was seen among smoking Danes; odds ratio 3.10 (95% confidence interval 1.07; 8.93), P = 0.03, but not among smoking Swedes; odds ratio 1.19 (95% confidence interval 0.41; 3.42), P = 0.75. Smoking is not a known risk factor for prostate cancer, and the association between CYP2D6 poor metabolism and prostate cancer in Danish smokers may have arisen by chance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471065     DOI: 10.1097/00008571-199906000-00008

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  24 in total

Review 1.  A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review.

Authors:  Chunming Gong; Xueying Hu; Yong Gao; Yunfei Cao; Feng Gao; Zengnan Mo
Journal:  Med Oncol       Date:  2010-01-23       Impact factor: 3.064

2.  Further evidence for null association of phenol sulfotransferase SULT1A1 polymorphism with prostate cancer risk: a case-control study of familial prostate cancer in a Japanese population.

Authors:  Hidekazu Koike; Haruki Nakazato; Nobuaki Ohtake; Hiroshi Matsui; Hironobu Okugi; Yasuhiro Shibata; Seiji Nakata; Hidetoshi Yamanaka; Kazuhiro Suzuki
Journal:  Int Urol Nephrol       Date:  2008-03-27       Impact factor: 2.370

3.  Variation in N-acetyltransferase 2 (NAT2), smoking and risk of prostate cancer in the Slovak population.

Authors:  Marta Vilčková; Jana Jurečeková; Dušan Dobrota; Viera Habalová; Lucia Klimčáková; Iveta Waczulíková; Peter Slezák; Ján Kliment; Monika Kmeťová Sivoňová
Journal:  Med Oncol       Date:  2014-05-11       Impact factor: 3.064

4.  N-acetyltransferase-2 gene polymorphisms and prostate cancer susceptibility in Latin American patients.

Authors:  Mario Maciel de Lima Junior; Leonardo Oliveira Reis; Ana Carolina Trindade Guilhen; Fabiana Granja; Mariana Nicolau de Lima Oliveira; Ubirajara Ferreira; Lucas Leite Cunha; Laura Sterian Ward
Journal:  Med Oncol       Date:  2012-01-14       Impact factor: 3.064

5.  Well-done meat consumption, NAT1 and NAT2 acetylator genotypes and prostate cancer risk: the multiethnic cohort study.

Authors:  Sangita Sharma; Xia Cao; Lynne R Wilkens; Jennifer Yamamoto; Annette Lum-Jones; Brian E Henderson; Laurence N Kolonel; Loïc Le Marchand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-06-22       Impact factor: 4.254

Review 6.  Association between the GSTP1 Ile105Val polymorphism and prostate cancer risk: a systematic review and meta-analysis.

Authors:  Zhuo Yu; Zhong Li; Bing Cai; Ziming Wang; Weimin Gan; Haiwen Chen; Hecheng Li; Peng Zhang; Hongliang Li
Journal:  Tumour Biol       Date:  2013-03-14

7.  Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico.

Authors:  Joel Salazar-Flores; Luis A Torres-Reyes; Gabriela Martínez-Cortés; Rodrigo Rubi-Castellanos; Martha Sosa-Macías; José F Muñoz-Valle; César González-González; Angélica Ramírez; Raquel Román; José L Méndez; Andrés Barrera; Alfredo Torres; Rafael Medina; Héctor Rangel-Villalobos
Journal:  Genet Test Mol Biomarkers       Date:  2012-08-22

8.  Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population.

Authors:  Wei-Xing Shi; Shu-Qing Chen
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

9.  MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status.

Authors:  Taro Iguchi; Shozo Sugita; Ching Y Wang; Nancy B Newman; Tatsuya Nakatani; Gabriel P Haas
Journal:  In Vivo       Date:  2009 Jan-Feb       Impact factor: 2.155

10.  Examination of polymorphic glutathione S-transferase (GST) genes, tobacco smoking and prostate cancer risk among men of African descent: a case-control study.

Authors:  Nicole A Lavender; Marnita L Benford; Tiva T VanCleave; Guy N Brock; Rick A Kittles; Jason H Moore; David W Hein; La Creis R Kidd
Journal:  BMC Cancer       Date:  2009-11-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.